Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other neoplasm 1

Conditions

Lung Neoplasms 4Pulmonary Disease, Chronic Obstructive 1Precancerous Conditions 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Peripheral Blood Stem Cell Transplantation 9Cyclophosphamide 9Biopsy 8fludarabine phosphate 7Whole-Body Irradiation 6Tacrolimus 5Mycophenolic Acid 5Epoetin Alfa 5Colposcopy 5Celecoxib 5Busulfan 5Aminolevulinic Acid 5Sulindac 4Selenium 4Methotrexate 4Melphalan 4Cyclosporine 4Cetuximab 4Antilymphocyte Serum 4Polymerase Chain Reaction 3Imiquimod 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Gene Expression Profiling 3Etoposide 3Eflornithine 3Darbepoetin alfa 3Carboplatin 3Aspirin 3fludarabine 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Precancerous Conditions × Iloprost × Clear all
NCT00084409 2020-05-14

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

University of Colorado, Denver

Phase 2 Completed
152 enrolled 18 charts
Other neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡